Gedatolisib (PKI-587)

Catalog No.S2628 Synonyms: PF-05212384

For research use only.

Gedatolisib (PF-05212384, PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ and mTOR with IC50 of 0.4 nM, 5.4 nM and 1.6 nM in cell-free assays, respectively. Phase 2.

Gedatolisib (PKI-587) Chemical Structure

CAS No. 1197160-78-3

Selleck's Gedatolisib (PKI-587) has been cited by 19 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Other PI3K Products

Biological Activity

Description Gedatolisib (PF-05212384, PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ and mTOR with IC50 of 0.4 nM, 5.4 nM and 1.6 nM in cell-free assays, respectively. Phase 2.
Targets
PI3Kα [1]
(Cell-free assay)
mTOR [1]
(Cell-free assay)
PI3Kγ [1]
(Cell-free assay)
0.4 nM 1.6 nM 5.4 nM
In vitro

PKI-587 shows potent inhibitory activity against PI3K-α, PI3K-γ and mTOR with IC50 of 0.4 nM, 5.4 nM and 1.6 nM, respectively. Furthermore, PKI-587 also exhibits its potency against the most frequently occurring mutant forms of PI3Kα, notably the H1047R and E545K with IC50 of 0.6 nM and 0.6 nM, respectively. [1] Correlated with suppression of phosphorylation of PI3K/mTOR signaling pathway proteins, PKI-587 causes tumor cell growth inhibition in MDA-361 and PC3-MM2 cell lines with IC50 of 4 nM and 13.1 nM, respectively. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MDA-MB-361 cells M{DqRmN6fG:2b4jpZ4l1gSCjc4PhfS=> M3;5fWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2zOlEh[2WubIOsJGlEPTB;MD6wNFQh|ryP NHHqTnozODF4Nk[5Oy=>
PC3MM2 cells NEnxU2tEgXSxdH;4bYNqfHliYYPzZZk> MXrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQR|NOVTJiY3XscJMtKEmFNUC9NE4xOTNzIN88US=> NHjwSo0zODF4Nk[5Oy=>
MDA-MB-361 cells MkHLSpVv[3Srb36gZZN{[Xl? MnPPTY5pcWKrdHnvckBw\iCDa4SgWFMxQCCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hVUSDLV3CMVM3OSClZXzsd{BjgSCZZYP0[ZJvKGKub4T0bY5oNCCLQ{WwQVAvODB6IN88US=> M4rZTVIxOTZ4Nkm3
MDA-MB-361 cells NUnre|V6TnWwY4Tpc44h[XO|YYm= NXPCcGRwUW6qaXLpeIlwdiCxZjDBb5QhWzR5MzDwbI9{eGixconsZZRqd25iaX6gbJVu[W5iTVTBMW1DNTN4MTDj[YxteyCkeTDX[ZN1\XKwIHLsc5R1cW6pLDDJR|UxRTBwMEGg{txO NWroSGk5OjBzNk[2PVc>
MDA-MB-361 cells NHzvbllHfW6ldHnvckBie3OjeR?= MULJcohq[mm2aX;uJI9nKGWQT2OgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIF3ERU1OSi1|NkGgZ4VtdHNiYomgW4V{fGW{bjDicI91fGmwZx?= NYPneFc1OjBzNk[2PVc>
MDA-MB-361 cells MVvGeY5kfGmxbjDhd5NigQ>? M4f0XGlvcGmkaYTpc44hd2ZiUFHSV|QxKHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBOTEFvTVKtN|YyKGOnbHzzJIJ6KFenc4Tldo4h[myxdITpcoc> M2\LTlIxOTZ4Nkm3
MDA-MB-361 cells MnuwSpVv[3Srb36gZZN{[Xl? NVGycFF2UW6qaXLpeIlwdiCxZjDHV2s{KGurbnHz[UBxcG:|cHjvdplt[XSrb36gbY4hcHWvYX6gUWRCNU2ELUO2NUBk\WyuczDifUBY\XO2ZYLuJIJtd3S2aX7n MkDCNlAyPjZ4OUe=
MDA-MB-361 cells M33iV2Z2dmO2aX;uJIF{e2G7 MVHJcohq[mm2aX;uJI9nKG2WT2KgWG9TSzFia3nuZZNmKGGldHn2bZR6KGmwIHj1cYFvKE2GQT3NRk0{PjFiY3XscJMh[XO|ZYPz[YQh[XNic4XwdJJme3Orb36gc4YheDdyU{\LJJBpd3OyaH;yfYxifGmxbjDheEA9KDNyIH7N MUGyNFE3PjZ7Nx?=
MDA-MB-361 cells Ml7vSpVv[3Srb36gZZN{[Xl? MnjuTY5pcWKrdHnvckBw\iCvVF;SJHRQWkNzIHvpcoF{\SCjY4Tpeol1gSCrbjDoeY1idiCPRFGtUWIuOzZzIHPlcIx{KGG|c3Xzd4VlKGG|IIP1dJBz\XO|aX;uJI9nKDSHQmCxJJBpd3OyaH;yfYxifGmxbjDheEA9KDNyIH7N NWSyWm55OjBzNk[2PVc>
MDA-MB-361 cells MoHrSpVv[3Srb36gZZN{[Xl? Mn7JTY5pcWKrdHnvckBw\iCDa4SgWFMxQCCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hVUSDLV3CMVM3OSClZXzsd{B5\W6xZ4Lh[pRm\CCvb4Xz[UBud2SnbDD1dJRwKDN4IHjydy=> NVrPeJZ2OjBzNk[2PVc>
MDA-MB-361 cells M37mXWZ2dmO2aX;uJIF{e2G7 NHq2WHhKdmirYnn0bY9vKG:oIFHreEBUPDd|IIDoc5NxcG:{eXzheIlwdiCrbjDoeY1idiCPRFGtUWIuOzZzIHPlcIx{KHinbn;ndoFnfGWmIH3veZNmKG2xZHXsJJVxfG9iM{[gbJJ{ MWqyNFE3PjZ7Nx?=
MDA-MB-361 cells Mkn6SpVv[3Srb36gZZN{[Xl? MYXJcoR2[3Srb36gc4YhWEGUUDDjcIVifmGpZTDpckBpfW2jbjDNSGEuVUJvM{[xJINmdGy|IIjlco9oemGodHXkJI1wfXOnIH3v[IVtKHWydH:gNVghcHK| Mn31NlAyPjZ4OUe=
MDA-MB-361 cells NX7lWFNFTnWwY4Tpc44h[XO|YYm= MYLBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPRFGtUWIuOzZzIHPlcIx{KHinbn;ndoFnfGWmIH3veZNmKG2xZHXsJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjD0eY1weiC4b3z1cYUh[XRiMkCgcYcwc2duIHn2JI9vKGSjeTCxMEA2NCB7 MXeyNFE3PjZ7Nx?=
SF9 insect cells NYfETHVTTnWwY4Tpc44h[XO|YYm= MWiyJIg> MnzpTY5pcWKrdHnvckBw\iCqdX3hckBRUTONYXzwbIEh\XiycnXzd4VlKGmwIGPGPUBqdnOnY4SgZ4VtdHNiYX\0[ZIhOiCqcoOgZpkh\my3b4Lld4NmdmOnIIDvcIFzcXqjdHnvckBie3OjeTygTWM2OD1yLkCwNFQh|ryP NHvkdnQzOTd4M{GzOC=>
SF9 insect cells M2TyVmZ2dmO2aX;uJIF{e2G7 MmnZNkBp MXvJcohq[mm2aX;uJI9nKGi3bXHuJHBKO0upYX3tZUBmgHC{ZYPz[YQhcW5iU1[5JIlve2WldDDj[YxteyCjZoTldkAzKGi{czDifUBndHWxcnXzZ4Vv[2VicH;sZZJqgmG2aX;uJIF{e2G7LDDJR|UxRTBwMEGx{txO MXKyNVc3OzF|NB?=
MDA-MB-361 cells NIDKdpdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4n1SVczKGh? Ml63S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUWRCNU2ELUO2NUBk\WyuczDh[pRmeiB5MjDodpMtKEmFNUC9NE4xODNizszN NXzRWFd4OjF5NkOxN|Q>
human PC3 cells MmCyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3q1RlczKGh? MWjHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDQR|Mh[2WubIOgZYZ1\XJiN{KgbJJ{NCCLQ{WwQVAvODFzIN88US=> NHu0Z2MzOTd4M{GzOC=>
Assay
Methods Test Index PMID
Growth inhibition assay Cell viability 29978469
Western blot p-AKT / p-mTOR / p-p70S6K / p-S6K / p-4E-BP1 / AKT / mTOR / p70S6K / S6K / 4EBP1 ; TSC1 / TSC2 / Raptor 29978469
In vivo In nude mice, PKI-587 treatment at 25 mg/kg iv leads to low plasma clearance (7 (mL/min)/kg), high volume of distribution (7.2 L/kg), and long half-life, (14.4 hours). In the MDA-361 xenograft model, PKI-587 produces potent antitumor efficacy with the minimum efficacious dose (MED) of 3 mg/kg against MDA-361 tumors and maximum tolerated single dose (MTD) of 30 mg/kg. While in the H1975 (non-small-cell lung carcinoma, mutant EGFR [L858R, T790M]) xenograft model, PKI-587 at 25 mg/kg for 7 weeks results in 90% survival of the group treated. [1]

Protocol (from reference)

Kinase Assay:[1]
  • PI3K and mTOR kinase assay :

    Enzyme assays are done in fluorescent polarization (FP) format, adapted from the Echelon K-1100 PI3K FP assay kit protocol. Human class I PI3Ks and PI3K-α mutants (E545K and H1047R) are produced in Sf9 or purchased from Upstate Biotech. GST-GRP1 (murine) is produced in Escherichia coli and isolated by GST-Sepharose. Assay buffers are reaction buffer [20 mM HEPES (pH 7.1), 2 mM MgCl2, 0.05% CHAPS, and 0.01% β-mercaptoethanol] and stop/detection buffer [100 mM HEPES (pH 7.5), 4 mM EDTA, 0.05% CHAPS]. FP reaction is run for 30 minutes at room temperature in 20 μL of reaction buffer containing 20 μM phosphatidylinositol 4,5-bisphosphate (PIP2), 25 μM ATP, and <4% DMSO. FP reaction is stopped with 20 μL of stop/detection buffer (10 nM probe and 40 nM GST-GRP), and after 2 hours, data are collected using an Envision plate reader. The routine assays with purified FLAG-TOR (FL and 3.5) are performed in 96-well plates as follows. Enzymes are first diluted in kinase assay buffer (10 mM Hepes (pH 7.4), 50 mM NaCl, 50 mM β-glycerophosphate, 10 mM MnCl2, 0.5 mM DTT, 0.25 μM microcystin LR, and 100 μg/mL BSA). To each well, 12 μL of the diluted enzyme is mixed briefly with 0.5 μL test inhibitor or control vehicle dimethyl sulfoxide (DMSO). The kinase reaction is initiated by adding 12.5 μL kinase assay buffer containing ATP and His6-S6K to give a final reaction volume of 25 μL containing 800 ng/mL FLAG-TOR, 100 μM ATP, and 1.25 μM His6-S6K. The reaction plate is incubated for 2 hours (linear at 1–6 hours) at room temperature with gentle shaking and then terminated by adding 25 μL Stop buffer (20 mM Hepes (pH 7.4), 20 mM EDTA, and 20 mM EGTA).

Cell Research:[1]
  • Cell lines: MDA-361 and PC3-MM2
  • Concentrations: 0-10 μM
  • Incubation Time: 72 hours
  • Method: Cells are plated in 96-well culture plates at about 3000 cells per well. One day following plating, PKI-587 is added to cells. Three days after PKI-587 treatment, viable cell densities are determined by measuring metabolic conversion (by viable cells) of the dye MTS, a previously established cell proliferation assay. For each assay, MTS and PMS stocks are freshly thawed and mixed (MTS/PMS, 20:1). The MTS/PMS mixture is then added to 96-well cell plates at 20 μL/well, and plates are incubated for 1 hour–2 hours in cell culture incubator. MTS assay results are read in a 96-well format plate reader by measuring absorbance at 490 nm. The effect of each PKI-587 treatment is calculated as a percentage of control cell growth obtained from vehicle-treated cells grown in the same culture plate.
Animal Research:[1]
  • Animal Models: MDA-361 and H1975 cells are injected subcutaneously into the nude mice.
  • Dosages: ≤30 mg/kg
  • Administration: Administered via i.v.

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 615.73
Formula

C32H41N9O4

CAS No. 1197160-78-3
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CN(C)C1CCN(CC1)C(=O)C2=CC=C(C=C2)NC(=O)NC3=CC=C(C=C3)C4=NC(=NC(=N4)N5CCOCC5)N6CCOCC6

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02438761 Terminated Drug: PF-05212384 Therapy-related Acute Myeloid Leukemia and Myelodysplastic Syndrome|Acute Myeloid Leukemia in Relapse|de Novo Acute Myeloid Leukemia at Diagnostic Institut Curie|Fondation ARC|National Cancer Institute France August 31 2015 Phase 2
NCT02069158 Completed Drug: PF-05212384|Drug: Paclitaxel|Drug: Carboplatin Breast Cancer|NSCLC|Ovary Cancer|Endometrial Cancer|Small Cell Lung Cancer (SCLC)|Head and Neck (HNSCC) Cristiana Sessa|Oncology Institute of Southern Switzerland April 2014 Phase 1
NCT01420081 Terminated Drug: PF-05212384 Endometrial Neoplasms Pfizer January 19 2012 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Gedatolisib (PKI-587) | Gedatolisib (PKI-587) supplier | purchase Gedatolisib (PKI-587) | Gedatolisib (PKI-587) cost | Gedatolisib (PKI-587) manufacturer | order Gedatolisib (PKI-587) | Gedatolisib (PKI-587) distributor